Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Total Non-current Liabilities
All obligations due after more than one year.
Apogee Therapeutics, Inc.NASDAQ: APGE
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities rises 1420.5% from a year ago
Total non-current liabilities stood at $103.7M at the end of Q2 FY2026, up 1420.5% from a year earlier and up 2012.4% from the prior quarter.
Context
- Total non-current liabilities amounted to 7.8% of total assets at the end of Q2 FY2026, up 6.7 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +1420.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.35M USD
- Year-over-year change
- -37.8%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.35M | -37.8% |
| FY2024 | 2024-12-31 | 8.6M | +821.4% |
| FY2023 | 2023-12-31 | 933K | — |
| FY2022 | 2022-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1420.5% is the highest of 10, against a peer median of -4.1%.
- Total non-current liabilities amounts to 7.8% of total assets for APGE, versus a peer median of 8.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.2B USD | +38.1% | +9.4% | 92.6% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥986.62M CNY | -16.2% | -13.8% | 24.9% |
| Jun 2026 | $754.13M USD | +659.6% | +109.4% | 91.1% | |
| Sep 2026 | $119.1M USD | -55.6% | -30.9% | 7.1% | |
| Mar 2026 | $117.84M USD | +0.4% | +19.0% | 18.4% | |
| Jun 2026 | $103.7M USD | +1420.5% | — | 7.8% | |
IRONDisc Medicine, Inc. | Sep 2026 | $60.88M USD | +100.8% | +209.4% | 8.7% |
| Jun 2026 | $39.17M USD | -4.1% | +5.5% | 3.6% | |
| Sep 2026 | $9.27M USD | -21.0% | +4.5% | 0.9% | |
| Sep 2026 | $8.19M USD | -18.0% | +230.2% | 0.7% | |
| Peer median (excluding APGE) | — | -4.1% | +9.4% | 8.7% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.